Ajanta Pharma Ltd Receives USFDA Inspection Report for Paithan Manufacturing Facility
Ajanta Pharma Ltd has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) concerning its manufacturing facility located in Paithan, Maharashtra.The USFDA conducted the Good Manufacturing Practices (cGMP) inspection of the Paithan facility between April 13, 2026, and April 21, 2026. The company has received the final report from the regulatory body.
Ajanta Pharma stated that the inspection has been classified as Voluntary Action Indicated (VAI). The successful completion of this critical inspection provides insight into the operational status of the facility.
AJANTPHARM Stock Price Movement
Shares of Ajanta Pharma Limited are shedding 0.75% in live trading as of 2:09 PM, with the stock currently valued at ₹3322.4. The movement was observed amidst a traded volume of 46,265 shares during the current session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.